| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Venus Concept Inc.
13D/A
VERO · 92332W303
|
100.0% |
3/30/2026
Event 3/26/2026
|
||||
| Madryn Asset Management, LP | 100.0% | |||||
| Madryn Health Partners, LP | 37.0% | |||||
| Madryn Health Partners (Cayman Master), LP | 63.0% | |||||
| Madryn Health Advisors, LP | 100.0% | |||||
|
Neuronetics, Inc.
13D/A
STIM · 64131A105
|
30.3% |
3/4/2026
Event 3/2/2026
|
||||
| Madryn Asset Management, LP | 30.3% | |||||
| Madryn Health Partners II, LP | 2.1% | |||||
| Madryn Health Partners II (Cayman Master), LP | 24.9% | |||||
| Madryn Health Advisors II, LP | 27.0% | |||||
| Madryn Health Advisors GP II, LLC | 27.0% | |||||
| Madryn Select Opportunities, LP | 3.3% | |||||
| Madryn Select Advisors, LP | 3.3% | |||||
| Madryn Select Advisors GP, LLC | 3.3% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.